Home LiteratureArticle Details
PMID: 18332465 Published · ppublish English Comment Editorial Review

Dose selection in phase I studies: why we should always go for the top.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology ·Vol. 26 ·No. 10 ·2008-04-01 ·Pages 1576-8

Sleijfer S, Wiemer E

Abstract

暂无摘要

MeSH Terms
Antineoplastic Agents/administration & dosage Clinical Trials, Phase I as Topic/methods Dose-Response Relationship, Drug Humans Maximum Tolerated Dose Neoplasms/drug therapy
Chemicals
Antineoplastic Agents
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Sleijfer Stefan
Wiemer Erik
Article Info
Journal
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Abbr.
J Clin Oncol
ISSN
1527-7755
DOI
10.1200/JCO.2007.15.5192
Published
2008-04-01
Epub
2008-00-10
Pages
1576-8
Language
English
Region
United States
NLM ID
8309333
Subset
IM
Corrections
CommentOn
PMID: 18332469
CommentOn
PMID: 18332470
CommentIn
PMID: 18640947
External Links
PubMed source DOI: 10.1200/JCO.2007.15.5192 View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2